06/01/2018 13:45:00

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with losses on their Investment in The Crypto Company of Class Action Lawsuit and Upcoming Deadline – CRCW

NEW YORK, Jan. 06, 2018 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against The Crypto Company (“Crypto” or the “Company”) (OTCMKTS:CRCW) and certain of its officers.   The class action, filed in United States District Court, for the Central District of California, and docketed under 17-cv-09157, is on behalf of a class consisting of investors who purchased or otherwise acquired Crypto securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Crypto securities between August 21, 2017, and December 18, 2017, both dates inclusive, you have until February 20, 2018, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here to join this class action]

The Crypto Company is engaged in the business of advising regarding, investing in, trading and developing proprietary source code for digital assets with diversified exposure to digital asset markets. The Company’s core services include consulting and advising companies regarding investment and trading in the digital asset market and investing in a manner that diversifies exposure to the growing class of digital assets. 

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Crypto unlawfully engaged in a scheme to promote and manipulate the Company’s stock; and (ii) as a result, Crypto’s public statements were materially false and misleading at all relevant times.

On December 19, 2017, the SEC temporarily suspended Crypto stock from trading due to concerns that the stock was being manipulated after the shares surged more than 17,000% in less than 3 months. The SEC said it was alarmed about “the accuracy and adequacy of information” relating to the compensation paid for promotion of its and statements in SEC filings about the plans of the Company’s insiders to sell their stock. Crypto stock was trading at $575 per share at the time trading was suspended and the suspension will remain in effect until January 3, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Oct
DANSKE
Stop dog for helvede dine sindsyge indlæg. Det er brugere som dig der fuldkommen smadrer det her for..
27
11 Oct
OMXC25
... og det betyder som regel, at det er sidste ben i nedturen, før en pause, eller en positiv modrea..
24
12 Oct
DANSKE
Ole Andersen havde ansat 5 kanibaler til at ryde op efter hvidvasskandalen. I har nu fast arbejde, t..
21
13 Oct
PNDORA
Carnegie's seneste analyse gav lidt medvind til pandora, men det var slet ikke meningen, idet alle j..
20
10 Oct
DANSKE
TYVERI FOR 100 MILLIONER - DANSKE BANKS ANSVAR?Igår kom en historie om en kvinde, der systematisk ig..
18
14 Oct
DANSKE
En korruptionsbekæmper skudt i Moskva, er nu også blevet Danske Banks skyld, hvor ussel kan denne p..
16
12 Oct
DANSKE
Der er noget ejendommeligt ved danmarkshistoriens formentlig største pengeinstitutskandale: Formentl..
15
13 Oct
CHEMM
@Tommy, Du stiller et meget relevant spørgsmål, men først vil jeg korrigere lidt på dit P/E. Som inv..
14
12 Oct
VELO
Blot til orientering. Kursudvikling i Veloxis vs. øvrige danske biotek/medico seneste måned: Velo..
14
15 Oct
OMXC25
Jeg har tænkt over den seneste uges udvikling. Min globale-US-dollars-allokerings-model (GUSDAM) vis..
13

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team
2
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
3
JCDecaux: Update on JCDecaux's proposed acquisition of APN Outdoor in Australia
4
Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
5
ACACIA PHARMA PROVIDES FURTHER UPDATE ON FDA REGULATORY REVIEW OF BARHEMSYS(TM)

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 October 2018 01:08:03
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181005.3 - EUROWEB7 - 2018-10-16 02:08:03 - 2018-10-16 01:08:03 - 1000 - Website: OKAY